Quel est le prix pour Molecular Pharmacology (USA), Ltd. (MLPH)

Le prix pour Molecular Pharmacology (USA), Ltd. (MLPH) est $0.0322

Quelle est la capitalisation boursière pour Molecular Pharmacology (USA), Ltd. (MLPH)

La capitalisation boursière pour Molecular Pharmacology (USA), Ltd. (MLPH) est $643.71K

Molecular Pharmacology (USA), Ltd. (MLPH) Prix et Capitalisation Boursière

As a development-stage company, Molecular Pharmacology (USA) Limited (MLPH) is dedicated to the creation and market introduction of solutions for pain and inflammation, with a primary focus on the Australian and United States markets. Through its subsidiary, Molecular Pharmacology Pty. Ltd., it is advancing an analgesic and anti-inflammatory molecule called Tripeptofen, designed to alleviate common daily pain. These products are offered in diverse dosage forms, formulations, and packaging options to suit various needs. MLPH's marketing strategy involves leveraging pharmaceutical distributors and forging collaborative partnerships with companies in the United States and Europe. Additionally, the company maintains an agreement with Dermatology Development Corporation to jointly develop and market a suite of therapeutic, cosmetic, and cosmeceutical items derived from the ThermaLIFE product line and its core active component. Headquartered in Perth, Australia, Molecular Pharmacology (USA) Limited operates as a subsidiary of PharmaNet Group Limited.

Prix pour MLPH	L’actif B	La capitalisation boursière de B	Résultats
$273,600 $643.71K	NVDA	$5.470T	+849,688,348.56%
$223,454 $643.71K	AAPL	$4.467T	+693,955,944.25%
$208,813 $643.71K	GOOG	$4.174T	+648,487,582.02%
$185,087 $643.71K	MSFT	$3.700T	+574,804,038.17%
$142,781 $643.71K	AMZN	$2.854T	+443,419,822.93%

Prix pour MLPH

L’actif B

La capitalisation boursière de B

Résultats

$273,600 $643.71K